Medical Institute visit days for patients with DME who received either anti-VEGF agents or a DEX-implant during the follow-up period
| Mean (days) | P value* | Median (days) | P value† | Unadjusted | Adjusted‡ | |||
| Anti-VEGF | DEX-implant | Anti-VEGF | DEX-implant | Visit ratio§ (95% CI) | Visit ratio (95% CI) | |||
| Total visits | 55.59 | 51.45 | 0.3124 | 39.00 | 40.00 | 0.5176 | 1.08 (1.06 to 1.11)¶ | 1.07 (1.04 to 1.09)¶ |
| Outpatient visits | 45.26 | 44.20 | 0.7074 | 36.50 | 37.00 | 0.5787 | 1.02 (1.00 to 1.05) | 1.05 (1.02 to 1.07)¶ |
| Eye care-related visits | 15.17 | 15.85 | 0.3449 | 14.00 | 14.00 | 0.4977 | 0.96 (0.92 to 1.00) | 0.96 (0.92 to 1.00) |
| Outpatient eye care-related visits | 14.97 | 15.14 | 0.8028 | 14.00 | 13.00 | 0.9359 | 0.99 (0.95 to 1.03) | 0.99 (0.95 to 1.04) |
Anti-VEGF includes ranibizumab and aflibercept. The total visits to medical care are the aggregated number of visits to all medical care used by the patient during a 1 year postindex period.
*Estimated p values based on the t-test.
†Estimated p values based on the Wilcoxon test.
‡Adjusted for baseline characteristics such as age, gender, CCI and health plan type.
§The reference values obtained from the DEX-implant as 1.
¶P<0.001
anti-VEGF, antivascular endothelial growth factor; DEX-implant, dexamethasone intravitreal implant; DME, diabetic macular oedema.